Carbapenems

DRUG3 trials

Sponsors

Phramongkutklao College of Medicine and Hospital, Shanxi Bethune Hospital, Oregon Health and Science University

Conditions

BacteremiaE Coli InfectionESBL Producing E.ColiFebrile NeutropeniaInfection, Bacterial

Phase 2

Cefotetan Therapy for Escherichia Coli Infections

Not yet recruitingNCT07318584

Oregon Health and Science UniversityE Coli Infection, ESBL Producing E.Coli

Start: 2026-03-31End: 2028-08-31Target: 84Updated: 2026-01-06

Unknown Phase

Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia

CompletedNCT03925402

Phramongkutklao College of Medicine and HospitalBacteremia, Infection, Bacterial

Start: 2019-05-15End: 2022-10-01Updated: 2023-03-29

Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.

RecruitingNCT07204522

Shanxi Bethune HospitalFebrile Neutropenia

Start: 2025-09-22End: 2027-09-22Target: 20Updated: 2025-10-02

Related Papers

Towards optimizing carbapenem selection in stewardship strategies: a prospective propensity score-matched study of ertapenem versus class 2 carbapenems for empirical treatment of third-generation cephalosporin-resistant Enterobacterales bacteraemia

Journal of Antimicrobial Chemotherapy2023-05-253 citations